Coiled Therapeutics plc
COIL · AIM · Health Care · mcap £26m · 6.1p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 01 Oct 26 | Investor Presentation via Engage Investor
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, announces that the leadership team will ho |
−1.3% | |
| 30 Sep 26 | Participation in The Small Cap Showcase
Coiled Therapeutics to present at The Small Cap Showcase investor conference in New York on 1 October 2026. |
+0.0% | |
| 28 Sep 26 | Director dealing | Director/PDMR Shareholding | |
| 28 Sep 26 | Results | Half-year Results
Coiled Therapeutics reports 80% clinical benefit rate for AO-252 in Phase I trial and raises £8.5m. |
+0.0% |
| 21 Sep 26 | Successful Enrolment Completed Across Two Cohorts
Enrolment completed across two cohorts of new AO-252 formulation in Phase I study. |
+0.0% | |
| 01 Sep 26 | Appointment of Joint Corporate Broker
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, is pleased to announce the appointment of |
+0.0% | |
| 10 Aug 26 | Routine | Change of Registered Office | |
| 03 Aug 26 | First Patient Dosed with new Formulation of AO-252
First patient dosed with optimised lipid-based formulation of AO-252, designed to improve drug exposure. |
+0.0% | |
| 07 Jul 26 | Coiled Advances Next-Generation AO-252 Formulation
Coiled advances next-generation lipid-based softgel formulation of AO-252 ahead of dose expansion. |
+5.3% | |
| 24 Jun 26 | Company Presentation
Company presentation available ahead of Proactive One2One Investor Forum appearance today. |
+0.0% | |
| 24 Jun 26 | Routine | Result of AGM | |
| 24 Jun 26 | Board change | Appointment of Independent Non-Executive Director
Craig Tooman appointed as Independent Non-Executive Director, effective 25 June 2026. |
+0.0% |
| 19 Jun 26 | Life Sciences Investor Forum
Chairman to present at Life Sciences Investor Forum on 25 June 2026. |
+0.0% | |
| 18 Jun 26 | Proactive One2One Investor Forum
Coiled Therapeutics to present at Proactive One2One Investor Forum on 24 June 2026. |
+0.0% | |
| 17 Jun 26 | Grant of Share Options
Coiled Therapeutics (AIM:COIL) (OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces it has granted 6,200,000 share options ("Options") over the Company's |
+0.0% | |
| 17 Jun 26 | Establishment of Medical Advisory Board
Coiled Therapeutics appoints two leading oncologists to newly established Medical Advisory Board for AO-252 development. |
+0.0% | |
| 08 Jun 26 | Appointment of Ozgur Sahin as Scientific Advisor
Professor Ozgur Sahin appointed as Scientific Advisor, first of planned Scientific Advisory Board appointments. |
+0.0% | |
| 29 May 26 | Routine | Issue of Equity | |
| 27 May 26 | Routine | Notice of AGM | |
| 19 May 26 | Commencement of Trading on US OTCQB Venture Market
Coiled Therapeutics commenced trading on US OTCQB Venture Market under ticker COTXF while maintaining AIM listing. |
+14.3% | |
| 07 May 26 | Attendance at Endless Frontier Labs 2026
Coiled Therapeutics selected for Endless Frontier Labs accelerator programme; CTO to present AO-252 at EFL Frontiers 2026 event. |
+0.0% | |
| 07 May 26 | Board change | Appointment of Non-Executive Director
Dr Andrew Dean appointed as Non-Executive Director, bringing oncology and clinical trials expertise. |
+0.0% |
| 06 May 26 | Results | Annual Report & Financial Statements
Clinical-stage oncology company reports 80% clinical benefit rate for lead asset AO-252 and raises £8.5m. |
+0.0% |
| 15 Apr 26 | Presentation at 18th Annual World Cancer Congress
Presentation at the 18th Annual World Cancer Congress |
+0.0% | |
| 08 Apr 26 | Clinical Trial Update
AO-252 twice-daily dosing achieves 80% clinical benefit rate versus 40% with once-daily in Phase I oncology trial. |
+8.8% | |
| 01 Apr 26 | Routine | Total Voting Rights | |
| 27 Mar 26 | Readmission - Roquefort Therapeutics Plc
NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON THE LONDON STOCK EXCHANGE |
−90.0% | |
| 27 Mar 26 | Routine | Admission to Trading and First Day of Dealings | |
| 26 Mar 26 | Investor Presentation
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that following the General Meeting held earlier today at which shareholders approved the acquisition of the exclusive worldwide licence |
−5.0% | |
| 26 Mar 26 | Routine | Result of General Meeting | |
| 25 Mar 26 | Lyramid SPA & MK Cell License Update
Longstop dates for sale of Lyramid and MK Cell out-license extended to 31 December 2026. |
+5.3% | |
| 02 Mar 26 | Schedule One - Roquefort Therapeutics PLC
Roquefort acquiring AO-252 licence from A2A and Coiled USA; rebranding to Coiled Therapeutics and raising £8.5m ahead of AIM readmission. |
+12.0% | |
| 02 Mar 26 | Fundraise | Proposed Acquisition and Fundraise of £8.5 million
Roquefort Therapeutics proposes to acquire worldwide licence to AO-252 cancer drug and raise £8.5m via placing. |
+12.0% |
| 25 Feb 26 | Transaction Update & Notice of Intention to Delist
Roquefort to acquire worldwide exclusive rights to AO-252 cancer drug candidate, move from Main Market to AIM. |
−9.1% | |
| 15 Jan 26 | Research Note Published
Research note published by broker SP Angel on proposed transaction with Coiled Therapeutics and A2A Pharmaceuticals. |
+8.3% | |
| 12 Dec 25 | Clinical Trial & License Agreement Update
Roquefort Therapeutics extends AO-252 license agreement longstop date to March 2026 and increases upfront consideration to £31.875m. |
+0.0% | |
| 09 Dec 25 | Conversion of CLNs
Convertible loan notes with face value of £80,000 converted into 6,282,264 ordinary shares. |
−3.7% | |
| 01 Dec 25 | Ex-Entitlement Date - Unlisted RNV Shares
Ex-entitlement date for Unlisted Redeemable Non-Voting Shares passed; ordinary shares marked ex-entitlement. |
−19.5% | |
| 01 Dec 25 | Determination of Record Date and Entitlement
Record date passed for issue of unlisted redeemable non-voting shares linked to Midkine Investments portfolio. |
−19.5% | |
| 25 Nov 25 | Holding | Holding(s) in Company | |
| 24 Nov 25 | Director dealing | Director/PDMR Shareholding | |
| 18 Nov 25 | Executed License Agreement & Transaction Update
Roquefort acquires worldwide exclusive rights to AO-252, a first-in-class oncology candidate, via share issue and equity raising; moving to AIM. |
+8.8% | |
| 03 Nov 25 | MK Cell Out-License & Lyramid SPA Update
Out-licensed MK Cell patents to Pleiades for up to US$25m milestones plus royalties; extended Lyramid sale deadline to January 2026. |
−8.1% | |
| 16 Oct 25 | Fundraise | Fundraise & Transaction Update
Roquefort raised £300,000 via advance subscriptions and loan to fund AO-252 licence acquisition from A2A Pharma and Coiled USA. |
−2.3% |
Company filings. Not investment advice.